Why Biotech is not a Bubble

I actually think it is a bubble – but a bubble that does not need to “burst” so to speak; one that can mature and begin to justify itself over the coming decade.

With aging populations accelerating across Europe, Japan, China and the US all at once – combined with the burgeoning middle class customer in the EM and its coming gentrification – the market for therapies and drugs is going into overdrive. This is probably why biotech stocks are selling at a 60% premium to the S&P 500 – double their already-rich historical premium.

The question, as always, remains the same – is it different this time? What has changed and are these changes permanent? Do these changes demand us to alter our way of thinking? Usually the answer is no, but sometimes it’s yes.

Here’s a very smart young blogger I’ve known for a few years, Elliot Turner, with his vociferous defense of the space and its current excesses (emphasis mine)…

The problem for biotech is that its impact is very intangible compared to the Smartphones we all carry in our pockets everywhere. Genomics has greatly accelerated the process and efficiency of drug discovery. The results are evident, though people don’t see or feel it. In 2012 new drug approvals by the FDA hit a sixteen year high. Although 2013 did not see a new high in approvals, it did see the largest aggregate market opportunity for new approvals. I will oversimplify to make the point very clear: let’s say the average drug development timeframe was 10 years and has now accelerated to 5 years. Drug development inherently becomes worth more money if the time to earning first cash flows is cut in half.

If you’re an investor or an enthusiast, you should read this:

BIOTECH: POPPING THE ALLEGATIONS OF A BUBBLE (Compounding My Interests)

This content, which contains security-related opinions and/or information, is provided for informational purposes only and should not be relied upon in any manner as professional advice, or an endorsement of any practices, products or services. There can be no guarantees or assurances that the views expressed here will be applicable for any particular facts or circumstances, and should not be relied upon in any manner. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment.

The commentary in this “post” (including any related blog, podcasts, videos, and social media) reflects the personal opinions, viewpoints, and analyses of the Ritholtz Wealth Management employees providing such comments, and should not be regarded the views of Ritholtz Wealth Management LLC. or its respective affiliates or as a description of advisory services provided by Ritholtz Wealth Management or performance returns of any Ritholtz Wealth Management Investments client.

References to any securities or digital assets, or performance data, are for illustrative purposes only and do not constitute an investment recommendation or offer to provide investment advisory services. Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others.

Wealthcast Media, an affiliate of Ritholtz Wealth Management, receives payment from various entities for advertisements in affiliated podcasts, blogs and emails. Inclusion of such advertisements does not constitute or imply endorsement, sponsorship or recommendation thereof, or any affiliation therewith, by the Content Creator or by Ritholtz Wealth Management or any of its employees. Investments in securities involve the risk of loss. For additional advertisement disclaimers see here: https://www.ritholtzwealth.com/advertising-disclaimers

Please see disclosures here.

What's been said:

Discussions found on the web
  1. bitcoin era review 2020 commented on Sep 28

    … [Trackback]

    […] Find More to that Topic: thereformedbroker.com/2014/02/22/why-biotech-is-not-a-bubble/ […]

  2. bitcoin evolution review commented on Oct 02

    … [Trackback]

    […] Info to that Topic: thereformedbroker.com/2014/02/22/why-biotech-is-not-a-bubble/ […]

  3. td canada easyweb commented on Nov 29

    … [Trackback]

    […] There you will find 78443 additional Information to that Topic: thereformedbroker.com/2014/02/22/why-biotech-is-not-a-bubble/ […]

  4. black leather louboutins replica commented on Dec 30

    … [Trackback]

    […] Find More to that Topic: thereformedbroker.com/2014/02/22/why-biotech-is-not-a-bubble/ […]